The "Clinical Overview and Clinical Summary: Creating Effective Marketing Authorisation Application Training Course" conference has been added to ResearchAndMarkets.com's offering. The Common ...

Greenberg Traurig is launching its second German office with a team of eight new hires including a former McDermott M&A and ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as ...

Hutchmed expects to record a gain of $477m from the deal and plans to invest the proceeds to develop its internal pipeline. See why I rate HCM stock a Hold.

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

Extended cash runway into late 2027, beyond a potentially registration-enabling azenosertib data readout from DENALI Part 2Planned workforce ...

An upstart biopharma firm founded by two former executives at CinCor Pharma – which celebrated a $1.8B exit to AstraZeneca in ...

RLS will continue to operate under the same name and as a standalone business within Telix Manufacturing Solutions (TMS), which includes other key Telix brands with multi-vendor and third-party ...

A new study by researchers from the Brown University School of Public Health found that pregnant women are regularly excluded ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...